The focus is on the potential impact of BRAFTOVI for patients with mCRC with a BRAF V600E mutation, reflecting Pfizer's dedication to providing innovative cancer treatments.

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium. The open-label ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...